Asset Details
Do you wish to reserve the book?
Isatuximab in the Treatment of Multiple Myeloma: A Review and Comparison With Daratumumab
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Isatuximab in the Treatment of Multiple Myeloma: A Review and Comparison With Daratumumab
Do you wish to request the book?
Isatuximab in the Treatment of Multiple Myeloma: A Review and Comparison With Daratumumab
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Isatuximab in the Treatment of Multiple Myeloma: A Review and Comparison With Daratumumab
2022
Overview
Multiple myeloma (MM) is a hematologic malignancy characterized by the proliferation of clonal plasma cells. Although advances in treatment have markedly improved survival outcomes for patients with MM, this disease is still considered incurable owing to its high incidence of relapse and refractoriness. Isatuximab is an anti-CD38 monoclonal antibody that can induce apoptosis in myeloma cells through a variety of mechanisms. Many clinical studies have demonstrated the efficacy and efficiency of isatuximab in both relapsed/refractory multiple myeloma (RRMM) and newly diagnosed multiple myeloma, leading to its approval for the treatment of adults with RRMM in combination therapies. In this review, the structure, mechanisms of action, pharmacokinetics, pharmacogenetics, and safety profile of isatuximab in MM are summarized. Additionally, isatuximab is compared with daratumumab in terms of mechanism and efficacy.
Publisher
SAGE Publications,Sage Publications Ltd,SAGE Publishing
Subject
/ Antibodies, Monoclonal - therapeutic use
/ Antibodies, Monoclonal, Humanized
/ Antineoplastic Combined Chemotherapy Protocols - therapeutic use
/ Humans
/ Multiple Myeloma - drug therapy
/ Multiple Myeloma - pathology
/ Neoplasm Recurrence, Local - drug therapy
/ Novel Biomarkers, Molecular Diagnostics and Targeted Therapies of Cancer
